Navigation Links
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Date:8/14/2008

SEATTLE, Aug. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated its second of two new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The multicenter trial, called ProACT (PROstate Active Cellular Therapy), has begun enrolling 120 patients with metastatic, androgen independent prostate cancer.

All patients will receive active treatment but will be randomized into one of three cohorts which will receive PROVENGE manufactured with different concentrations of the immunizing antigen. Patients will receive three infusions of PROVENGE, each two weeks apart. The trial is being conducted by Dendreon to explore the effect of antigen concentration on CD54 upregulation, a measure of product potency, as well as the immune response. Overall survival data will also be collected. The enrollment criteria are essentially the same as the criteria for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) study, which completed enrollment in October 2007 and, upon receipt of positive data, will serve as the primary study for amending Dendreon's Biologics License Application (BLA) for PROVENGE.

"We are grateful for the continued support from patients, physicians and patient advocates and are pleased to be able to provide them with access to PROVENGE while we await results from the IMPACT trial," stated Mitchell H. Gold, president and chief executive officer of Dendreon.

ProACT is the second of two studies the Company is initiating. Dendreon recently announced it had begun enrolling patients in a 40-subject, single-center trial called Neo
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014 Deep Research Report on Global and ... study on the current state of the Nano Silver ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:7/12/2014)... July 12, 2014 This ... reagents used in the life science industry. ... life science reagents market towards remarkable growth. ... and providers of life science reagents. , ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2
... The Oklahoma Medical,Research Foundation ("OMRF") and Alexion ... has agreed to acquire from OMRF,all rights to ... The patents cover inventions made by OMRF ... system mediated disorders, to which Alexion has had,limited ...
... Nanotechnology researchers are developing the perfect complement to the ... to power small electronic devices for soldiers in the ... harnessed and converted to electrical energy. , The February ... of textile fibers covered with zinc oxide nanowires can ...
... FRAZER, Pa., Feb. 13 Cephalon, Inc., (Nasdaq:,CEPH) ... complaint filed today,by the U.S. Federal Trade Commission ... Columbia challenging the validity of certain agreements entered,into ... 2006 to settle the PROVIGIL(R),(modafinil) [C-IV] patent infringement ...
Cached Biology Technology:Alexion Acquires All Rights to OMRF Patents Related to Soliris(R) 2Alexion Acquires All Rights to OMRF Patents Related to Soliris(R) 3Fiber-based nanotechnology in clothing could harvest energy from physical movement 2Fiber-based nanotechnology in clothing could harvest energy from physical movement 3Fiber-based nanotechnology in clothing could harvest energy from physical movement 4Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 3
(Date:7/11/2014)... the Wildlife Conservation Society shows that no-take zones ... species such as lobster, conch, and fish recover ... reef areas. , The reporttitled "Review of the ... research literature from no-take areas around the world. ... a recognized expert in marine protected areas and ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... fires burning in eastern New South Wales, Australia when ... At 03:35 UTC on July 11 (12:35 p.m. local ... over eastern New South Wales (NSW), the Moderate Resolution ... of the region and spotted smoke (light brown) from ... bands, are outlined in red. , The New South ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... bridge that spans a river to connect two major ... information flowing between the left and right hemispheres of ... Technology (Caltech) have found that people who are born ... callosum, or AgCCstill show remarkably normal communication across the ...
... survey in the world,s most biologically diverse landscape, researchers ... jaguars than ever before. Using technology first adapted ... identified 19 individual jaguars by spot patterns in the ... camera trap survey in the country. The animals ...
... fundamental physical principle relating to the behavior of dynamical ... system each individual particle behaves just as "chaotically" as ... one can extrapolate from the behavior of a single ... in spite of its wide-ranging implications, the theorem has ...
Cached Biology News:Bridging the gap 2Bridging the gap 3Wildlife Conservation Society uncovers record number of jaguars in Bolivia 2Glowing beacons reveal hidden order in dynamical systems 2Glowing beacons reveal hidden order in dynamical systems 3
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: